PEP-Therapy Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1.76M

  • Investors
  • 15

PEP-Therapy General Information

Description

Developer of peptides designed to offer targeted therapies for severe diseases, with an initial focus on oncology. The company's peptides offer intracellular drug delivery technology, cell-penetrating peptide capabilities, and targeted transport of therapeutic molecules to improve the delivery of therapeutic compounds, enabling pharmaceutical and biotechnology organizations to develop intracellular therapies with improved cellular access and therapeutic effectiveness.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Pépinière Genopole Entreprises
  • 4 rue Pierre Fontaine
  • 91058 Evry Cedex
  • France
+33 01
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Pépinière Genopole Entreprises
  • 4 rue Pierre Fontaine
  • 91058 Evry Cedex
  • France
+33 01

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PEP-Therapy Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Later Stage VC 01-Jan-2024 $1.76M Completed Clinical Trials - General
12. Secondary Transaction - Private 01-Sep-2021 Completed Clinical Trials - General
11. Later Stage VC (Series A) 19-Jul-2021 Completed Clinical Trials - General
10. Grant 22-Apr-2021 Completed Clinical Trials - General
9. Later Stage VC 31-Oct-2020 Completed Pre-Clinical Trials
8. Early Stage VC 16-Nov-2017 Completed Pre-Clinical Trials
7. Early Stage VC Completed Pre-Clinical Trials
6. Grant 01-Jan-2016 Completed Pre-Clinical Trials
5. Seed Round 27-Apr-2015 $1.4M $1.4M Completed Pre-Clinical Trials
4. Accelerator/Incubator Completed Pre-Clinical Trials
To view PEP-Therapy’s complete valuation and funding history, request access »

PEP-Therapy Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
P3 Shares
P2 Shares
O Shares
P shares
P shares
Preference 11,250 $1.092273 $116.51 $116.51 1x $116.51 8.83%
Ordinary 19,500 $1.092273 $72.82 $72.82 1x $72.82 15.31%
To view PEP-Therapy’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

PEP-Therapy Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of peptides designed to offer targeted therapies for severe diseases, with an initial focus on oncology. The c
Drug Discovery
Evry Cedex, France
12 As of 2022

San Diego, CA
 

Leeds, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PEP-Therapy Competitors (32)

One of PEP-Therapy’s 32 competitors is BPS Bioscience, a Corporation company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BPS Bioscience Corporation San Diego, CA
4D pharma Corporation Leeds, United Kingdom
Vir Biotechnology Formerly VC-backed San Francisco, CA
Oncodesign Services Private Equity-Backed Dijon, France
Sygnature Discovery Private Equity-Backed Nottingham, United Kingdom
You’re viewing 5 of 32 competitors. Get the full list »

PEP-Therapy Patents

PEP-Therapy Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3086387-A1 Cell penetrating peptides with improved internalization properties Inactive 22-Dec-2016
EP-3559673-A1 Cell penetrating peptides with improved internalization properties Active 22-Dec-2016
EP-3559673-B1 Cell penetrating peptides with improved internalization properties Active 22-Dec-2016
US-10947276-B2 Cell penetrating peptides with improved internalization properties Active 22-Dec-2016
US-20190337985-A1 Cell penetrating peptides with improved internalization properties Active 22-Dec-2016 G01N33/68
To view PEP-Therapy’s complete patent history, request access »

PEP-Therapy Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PEP-Therapy Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
CapHorn Invest Venture Capital Minority
Key Ventures Venture Capital Minority
Anaxago Real Estate Minority
Doorway Capital PE/Buyout Minority
i&i Prague Accelerator/Incubator Minority
You’re viewing 5 of 15 investors. Get the full list »

PEP-Therapy FAQs

  • When was PEP-Therapy founded?

    PEP-Therapy was founded in 2014.

  • Where is PEP-Therapy headquartered?

    PEP-Therapy is headquartered in Evry Cedex, France.

  • What is the size of PEP-Therapy?

    PEP-Therapy has 12 total employees.

  • What industry is PEP-Therapy in?

    PEP-Therapy’s primary industry is Drug Discovery.

  • Is PEP-Therapy a private or public company?

    PEP-Therapy is a Private company.

  • What is the current valuation of PEP-Therapy?

    The current valuation of PEP-Therapy is .

  • What is PEP-Therapy’s current revenue?

    The current revenue for PEP-Therapy is .

  • How much funding has PEP-Therapy raised over time?

    PEP-Therapy has raised $13.3M.

  • Who are PEP-Therapy’s investors?

    CapHorn Invest, Key Ventures, Anaxago, Doorway Capital, and i&i Prague are 5 of 15 investors who have invested in PEP-Therapy.

  • Who are PEP-Therapy’s competitors?

    BPS Bioscience, 4D pharma, Vir Biotechnology, Oncodesign Services, and Sygnature Discovery are some of the 32 competitors of PEP-Therapy.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process